1 Star2 Stars3 Stars4 Stars5 Stars (1 votes, average: 5.00 out of 5)

Buy Ceftin Online Without Prescription

Buy Ceftin Online With Low Price

Support Drug Guide: purchase the best generic medicine from our sponsor, online pharmacy store, where you can place an order and buy generic Ceftin online over the counter at lowest prices, worldwide delivery. Prices for Ceftin (Cefuroxime) according to the dosage forms and number of pills. The more pills in a package, the lower the price for 1 pill!

Buy Ceftin with VISA Buy generic Ceftin with MasterCard Bitcoint Secured by GeoTrust SSL: We offer the highest grade, 256-bit strength SSL Certificates through our official partner, GeoTrust. Online Pharmacy continues to meet the highest standards in the field of security with the implementation of McAfee Secure (formally Hacker Safe), the leading security certification service and provider on the Internet. Security Metrics: Certified and Credit Card Safe transactions. Generic Ceftin as effective as brand-name drug! Shipping: Ceftin delivery by U.S. Postal Service

The price of the product includes the shipping rate 9.95$.

Buy Cefuroxime Online

Cefuroxime is authorised in the world under the following brand names: Ancef, Biofuroksym, Cedax, Cefizox, Cefobid, Cefotan, Ceftin, Cefurax, Cefuril, Cefzil, Cepazine, Cephuroxime, Duricef, Elobact, Kefurox, Kefzol, Kerurox, Mandol, Maxipime, Mefoxin, Monocid, Oraxim, Rocephin, Sharox, Velosef, Zinacef, Zinat, Zinnat.

Where to buy Ceftin in the USA? Where can you buy Cefuroxime OTC in the UK? Cefuroxime for sale in Australia How much does Ceftin cost without insurance from Canada? Price of generic Cefuroxime in France Buy generic Ceftin from India online for the cheapest prices Cheap Cefuroxime is available to buy in Ireland Order Cefuroxime in Italy online How to buy Cefuroxime for cheap in New Zealand? Can you buy Cefuroxime over the counter in Spain?

Cefuroxime Axetil

Cefuroxime axetil (GSK’s Ceftin/Zinnat/Oracef) is a second-generation cephalosporin consisting of an esterified pro-drug of cefuroxime created for oral formulation; the active antibiotic metabolite cefuroxime is released after cefuroxime axetil absorption from the gastrointestinal tract. First launched in the United States in 1988, cefuroxime axetil was available as a generic in the United States by 2002. Cefuroxime is active against a broad spectrum of gram-positive and gram-negative bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, E. coli, H. influenzae, K. pneumoniae, and M. catarrhalis.

Cefuroxime Axetil

Cefuroxime axetil is indicated for a number of bacterial infections, including RTIs caused by β-lactam  ase-negative strains of S. pneumoniae, H. influenzae, M. catarrhalis, and Haemophilus parainfluenzae. A multicenter trial of 185 patients hospitalized with community-acquired pneumonia compared the efficacy of two dosing regimens of cefuroxime axetil (250 mg twice daily and 500 mg twice daily) with cefaclor (500 mg three times daily). The 250 mg dose group had a 90% favorable clinical response (58% cured, 32% clinically improved); the 500 mg cefuroxime axetil group had a 98% favorable clinical response (94% cured, 4% clinically improved). The third group of patients receiving cefaclor had a 97% favorable clinical response (88% cured, 9% clinically improved).

In clinical trials for cefuroxime axetil, patients who received seven to ten days of therapy experienced adverse reactions similar in type and frequency to adverse reactions associated with other antibiotic agents. Diarrhea (3.7%) and nausea/vomiting (3.0%) were among the most common reactions in trials with adults receiving tablets, while pediatric patients receiving the oral formulation experienced diarrhea (8.6%), dislike of taste (5.0%), diaper rash (3.6%), and nausea/vomiting (2.6%).

Cefuroxime Axetil


Cefprozil (Bristol-Myers Squibb’s [BMS’s] Cefzil/Procef/Bisoral) is a second-generation oral cephalosporin. The agent has been available in the United States since 1992 and has been marketed in a few European countries (Italy, Spain, and the United Kingdom). The agent is expected to have patent protection until 2006 in the United States and between 2004 and 2008 in the European markets. Cefprozil is active against gram-positive and gram-negative bacteria, but not Pseudomonas species. In clinical studies, cefprozil proved active against S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, and M. catarrhalis.


Although cefprozil is not specifically indicated for community-acquired pneumonia (the agent is approved for other RTIs, including acute exacerbations of chronic bronchitis [AECB], pharyngitis, otitis media, and acute sinusitis), one comparative clinical trial used cefprozil and cefaclor in the treatment of pneumonia. Of 90 patients who received 500 mg of cefprozil twice per day, 74 (82%) showed a clinical response; of 67 patients who received 500 mg of cefaclor every eight hours, 53 (79%) demonstrated a clinical response.

In clinical trials for cefprozil, side effects included nausea, diarrhea, vomiting, and abdominal pain.

Leave a Reply
Notify of